Neoadjuvant HER2 inhibition induces ESR1 DNA methylation alterations resulting in clinically relevant ER expression changes in breast cancers

Gavin P. Dowling; Gordon R. Daly; Aisling Hegarty; Michael Flanagan; Mihaela Ola; Ramón Fallon; Sinéad Cocchiglia; Vikrant Singh; Katherine M. Sheehan; Fiona Bane; Jason McGrath; Louise Watson; Sandra Hembrecht; Bryan Hennessy; Patrick G. Morris; Arnold D. K. Hill; Damir Varešlija; Leonie S. Young

doi:10.1002/cac2.12640

Cancer Communications ›› 2025, Vol. 45 ›› Issue (02) : 198 -202. DOI: 10.1002/cac2.12640

LETTER TO THE JOURNAL

Neoadjuvant HER2 inhibition induces ESR1 DNA methylation alterations resulting in clinically relevant ER expression changes in breast cancers

Author information +

History +

PDF

Cite this article

Download citation ▾

Gavin P. Dowling, Gordon R. Daly, Aisling Hegarty, Michael Flanagan, Mihaela Ola, Ramón Fallon, Sinéad Cocchiglia, Vikrant Singh, Katherine M. Sheehan, Fiona Bane, Jason McGrath, Louise Watson, Sandra Hembrecht, Bryan Hennessy, Patrick G. Morris, Arnold D. K. Hill, Damir Varešlija, Leonie S. Young. Neoadjuvant HER2 inhibition induces ESR1 DNA methylation alterations resulting in clinically relevant ER expression changes in breast cancers. Cancer Communications, 2025, 45(02): 198-202 DOI:10.1002/cac2.12640

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Uzun M, Atag E, Caliskan Yildirim E, Keser M, Semiz HS, Unal OU. Does immunohistochemical marker conversion affect the prognosis in breast cancer patients receiving neoadjuvant chemotherapy? Sci Rep. 2024; 14(1): 14651.

[2]	Grinda T, Joyon N, Lusque A, Lefèvre S, Arnould L, Penault-Llorca F. et al. Phenotypic discordance between primary and metastatic breast cancer in the large-scale real-life multicenter French ESME cohort. NPJ Breast Cancer. 2021; 7(1): 41.

[3]	Varešlija D, Priedigkeit N, Fagan A, Purcell S, Cosgrove N, O’Halloran PJ, et al. Transcriptome Characterization of Matched Primary Breast and Brain Metastatic Tumors to Detect Novel Actionable Targets. J Natl Cancer Inst. 2019; 111(4): 388-98.

[4]

Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet. 2010; 375(9712): 377-84.

[5]	Zhao M, Kim P, Mitra R, Zhao J, Zhao Z. TSGene 2.0: an updated literature-based knowledgebase for tumor suppressor genes. Nucleic Acids Res. 2016; 44(D1): D1023-31.

[6]	Giuliano M, Hu H, Wang YC, Fu X, Nardone A, Herrera S, et al. Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy. Clin Cancer Res. 2015; 21(17): 3995-4003.

[7]	Brasó-Maristany F, Griguolo G, Pascual T, Paré L, Nuciforo P, Llombart-Cussac A. et al. Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade. Nat Commun. 2020; 11(1): 385.

[8]	Han Y, Wu Y, Xu H, Wang J, Xu B. The impact of hormone receptor on the clinical outcomes of HER2-positive breast cancer: a population-based study. International Journal of Clinical Oncology. 2022; 27(4): 707-16.

[9]	Croessmann S, Formisano L, Kinch LN, Gonzalez-Ericsson PI. Sudhan DR, Nagy RJ, et al. Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer. Clin Cancer Res. 2019; 25(1): 277-89.

[10]

Johnston SRD, Hegg R, Im SA, Park IH, Burdaeva O, Kurteva G, et al. Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positiv. Metastatic Breast Cancer: Updated Results of ALTERNATIVE. J Clin Oncol. 2021; 39(1): 79-89.